In vitro Pharmacokinetics/Pharmacodynamics Evaluation of Fosfomycin Combined with Amikacin or Colistin against KPC2-Producing Klebsiella pneumoniae

被引:19
|
作者
Yu, Wei [1 ,2 ]
Zhou, Kai [1 ]
Guo, Lihua [1 ]
Ji, Jinru [1 ]
Niu, Tianshui [1 ]
Xiao, Tingting [1 ]
Shen, Ping [1 ]
Xiao, Yonghong [1 ]
机构
[1] Zhejiang Univ, State Key Lab Diag & Treatment Infect Dis, Collaborat Innovat Ctr Diag & Treatment Infect Di, Affiliated Hosp 1,Coll Med, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Prov Peoples Hosp, Dept Infect Dis, Hangzhou, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
pharmacokinetics/pharmacodynamics; fosfomycin; amikacin; colistin; KPC-producing Klebsiella pneumoniae; PLUS FOSFOMYCIN; ENTEROBACTERIACEAE; PHARMACOKINETICS; COMBINATION; PARAMETERS; THERAPY;
D O I
10.3389/fcimb.2017.00246
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: The emergence of carbapenem-resistant Enterobacteriaceae, especially Klebsiella pneumoniae, has become a major concern in clinic settings. Combination therapy is gaining momentum to counter the secondary resistance and potential suboptimal efficacy of monotherapy. The aim of this study was to evaluate the bactericidal effect of fosfomycin (FM), amikacin (AMK), or colistin (COL) alone and combinations against KPC2-producing K. pneumoniae using dynamic model by simulating human pharmacokinetics in vitro. Methods: The Pharmacokinetics Auto Simulation System 400 system was employed to simulate different dosing regimens of FM, AMK, and COL alone and combination. Bacterial growth recovery time (PT) and the area between the control growth and antibacterial killing curves (IE) were used as unbiased and comprehensive means for determining the antimicrobial effect. Results: We observed that COL alone was much pronounced than FM or AMK against KPC-Kp. IF of FM (8g every 8 h) plus AMK (15 mg/kg once-daily) and FM (8g every 8 h) plus COL (75,000 IU/kg every 12 h) were higher (>170 and >200 LogCFU/mL-h(-1), respectively) than that of monotherapies against sensitive strains. Of note, the rate of resistance was lower when using the combination of FM (8 g every 8 h) plus COL (75,000 IU/kg every 12 h) than using COL (75,000 IU/kg every 12 h) alone. Conclusions: The combination of FM (8g every 8 h) plus AMK (15 mg/kg once-daily) and FM (8 g every 8 h) plus COL (75,000 IU/kg every 12 h) were effective at maximizing bacterial killing and suppressing emergence of resistance.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] In vitro pharmacokinetics/pharmacodynamics evaluation of fosfomycin combined with amikacin or colistin against KPC2-producing Klebsiella pneumoniae
    Yu, W.
    Shen, P.
    Bao, Z.
    Zhou, K.
    Zheng, B.
    Ji, J.
    Guo, L.
    Huang, C.
    Xiao, Y.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 : S124 - S124
  • [2] Pharmacodynamics of colistin and fosfomycin: a 'treasure trove' combination combats KPC-producing Klebsiella pneumoniae
    Zhao, Miao
    Bulman, Zackery P.
    Lenhard, Justin R.
    Satlin, Michael J.
    Kreiswirth, Barry N.
    Walsh, Thomas J.
    Marrocco, Amanda
    Bergen, Phillip J.
    Nation, Roger L.
    Li, Jian
    Zhang, Jing
    Tsuji, Brian T.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (07) : 1985 - 1990
  • [3] In vitro antibacterial activity of fosfomycin combined with other antimicrobials against KPC-producing Klebsiella pneumoniae
    Yu, Wei
    Shen, Ping
    Bao, Zhang
    Zhou, Kai
    Zheng, Beiwen
    Ji, Jinru
    Guo, Lihua
    Huang, Chen
    Xiao, Yonghong
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 50 (02) : 237 - 241
  • [4] In vitro synergistic activity of fosfomycin in combination with meropenem, amikacin and colistin against OXA-48 and/or NDM-producing Klebsiella pneumoniae
    Sengel, Buket Erturk
    Gelmez, Gulsen Altinkanat
    Soyletir, Guner
    Korten, Volkan
    [J]. JOURNAL OF CHEMOTHERAPY, 2020, 32 (05) : 237 - 243
  • [5] Evaluation of antimicrobial combinations against colistin-resistant carbapenemase (KPC)-producing Klebsiella pneumoniae
    Maraki, S.
    Papadakis, I. S.
    [J]. JOURNAL OF CHEMOTHERAPY, 2015, 27 (06) : 348 - 352
  • [6] In Vitro Interactions of Antimicrobial Combinations with Fosfomycin against KPC-2-Producing Klebsiella pneumoniae and Protection of Resistance Development
    Souli, Maria
    Galani, Irene
    Boukovalas, Stefanos
    Gourgoulis, Michael George
    Chryssouli, Zoi
    Kanellakopoulou, Kyriaki
    Panagea, Theofano
    Giamarellou, Helen
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (05) : 2395 - 2397
  • [7] In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae
    Romanelli, Federica
    De Robertis, Annalisa
    Carone, Gianluca
    Dalfino, Lidia
    Stufano, Monica
    Del Prete, Raffaele
    Mosca, Adriana
    [J]. NEW MICROBIOLOGICA, 2020, 43 (03): : 136 - 138
  • [8] In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae
    Poudyal, Anima
    Howden, Benjamin P.
    Bell, Jan M.
    Gao, Wei
    Owen, Roxanne J.
    Turnidge, John D.
    Nation, Roger L.
    Li, Jian
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (06) : 1311 - 1318
  • [9] Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae
    Albiero, James
    Sy, Sherwin K. B.
    Mazucheli, Josmar
    Caparroz-Assef, Silvana Martins
    Costa, Bruno Buranello
    Borges Alves, Janio Leal
    Gales, Ana Cristina
    Bronharo Tognim, Maria Cristina
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (07) : 4128 - 4139
  • [10] In Vitro and In Vivo Synergism of Fosfomycin in Combination with Meropenem or Polymyxin B against KPC-2-Producing Klebsiella pneumoniae Clinical Isolates
    Ribeiro, Aghata Cardoso da Silva
    Chikhani, Yohanna Carvalho dos Santos Aoun
    Valiatti, Tiago Barcelos
    Valencio, Andre
    Kurihara, Mariana Neri Lucas
    Santos, Fernanda Fernandes
    Minarini, Luciene Andrade da Rocha
    Gales, Ana Cristina
    [J]. ANTIBIOTICS-BASEL, 2023, 12 (02):